1-5 of 5
David M. Lucas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells

Sneha V. Gupta, Erin Hertlein, Yanhui Lu, Ellen J. Sass, Rosa Lapalombella, Timothy L. Chen, Melanie E. Davis, Jennifer A. Woyach, Amy Lehman, David Jarjoura, John C. Byrd, David M. Lucas
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2406–2419.
https://doi.org/10.1158/1078-0432.CCR-12-2754
Published: 30 April 2013
View article titled, The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells
Open the PDF for The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-κB Response in Chronic Lymphocytic Leukemia Cells in another window
Includes: Supplementary data
Journal Articles

Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol

Lapo Alinari, Courtney J. Prince, Ryan B. Edwards, William H. Towns, Rajeswaran Mani, Amy Lehman, Xiaoli Zhang, David Jarjoura, Li Pan, A. Douglas Kinghorn, Michael R. Grever, Robert A. Baiocchi, David M. Lucas
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4600–4611.
https://doi.org/10.1158/1078-0432.CCR-12-0839
Published: 30 August 2012
View article titled, Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol
Open the PDF for Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol in another window
Journal Articles

Methylation and Silencing of Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia

Tasneem Motiwala, Sarmila Majumder, Huban Kutay, David Spencer Smith, Donna S. Neuberg, David M. Lucas, John C. Byrd, Michael Grever, Samson T. Jacob
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3174–3181.
https://doi.org/10.1158/1078-0432.CCR-06-1720
Published: 01 June 2007
View article titled, Methylation and Silencing of Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia
Open the PDF for Methylation and Silencing of Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia in another window
Journal Articles

Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab

Jesús G. Berdeja, Allan Hess, David M. Lucas, Paul O'Donnell, Richard F. Ambinder, Louis F. Diehl, Denise Carter-Brookins, Susan Newton, Ian W. Flinn
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (8): 2392–2399.
https://doi.org/10.1158/1078-0432.CCR-06-1860
Published: 16 April 2007
View article titled, Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab
Open the PDF for Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab in another window
Journal Articles

Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity

Syed-Rehan A. Hussain, Carolyn M. Cheney, Amy J. Johnson, Thomas S. Lin, Michael R. Grever, Michael A. Caligiuri, David M. Lucas, John C. Byrd
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2144–2150.
https://doi.org/10.1158/1078-0432.CCR-06-2294
Published: 02 April 2007
View article titled, Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity
Open the PDF for Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity in another window